QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=6522F86583777FE9575FA63A04BFDCC9;jsessionid=8F12C34BC9D825CC65D5EF4ABA58B4A8;jsessionid=796D931F85F68EC940CD8E0842D24364;jsessionid=352ACAAEABC826AF44A48161DE7E45B5;jsessionid=DB3CA8D9D418F9F8D49F7602C89EBD35 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=6522F86583777FE9575FA63A04BFDCC9;jsessionid=8F12C34BC9D825CC65D5EF4ABA58B4A8;jsessionid=796D931F85F68EC940CD8E0842D24364;jsessionid=352ACAAEABC826AF44A48161DE7E45B5;jsessionid=DB3CA8D9D418F9F8D49F7602C89EBD35